Author + information
- Zhang Lu,
- Huadong Liu,
- Xinli Pang and
- Shaohong Dong
The benefits of aspirin substantially exceed the risks for secondary prevention, while the balance between vascular events avoided and major bleeds caused by aspirin is uncertain for asymptomatic patients without cardiovascular disease. Thus we aim to further understand the effect of aspirin with this meta-analysis of randomized controlled trials.
We conducted a search in Medline, Embase, and Cochrane database. The language was restricted in English without time limit. Risk Ratio(RR) and 95% confidence interval(CI) were used as the summary statistic. Fixed-effects model was used unless heterogeneity was high.
Thirteen studies with 161,281 participants were enrolled. Aspirin reduced myocardial infarction events(Fig 1). The article demonstrated a significant reduction in ischemia stroke (RR 0.91, 95%CI 0.84-0.98). As cardiovascular mortality was concerned, aspirin showed no benefit. There was marginal difference for all cause mortality. Not surprisingly, aspirin therapy resulted in more risk in respect to gastrointestinal bleeding(RR 1.60, 95%CI 1.30-1.96). Meanwhile, aspirin was proven to be harmful in hemorrhagic stroke(RR 1.25, 95%CI 1.02-1.53).
Overall, we present the largest meta-analysis in this area so for. Aspirin was provened to reduce both myocardial infarction and stroke. However, the benefits are blunted by bleeding events. Hence, we should individualize the therapy with the art of balance.
Poster Hall, Hall F
Saturday, March 16, 2019, 10:00 a.m.-10:45 a.m.
Session Title: Prevention: Clinical 1
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1134-436
- 2019 American College of Cardiology Foundation